ImmunityBio (IBRX) stock drew fresh attention after the company appointed Dr. Jim Yong Kim as Vice Chairman, reflecting a push to deepen global partnerships and support wider access to its immunotherapy programs.
See our latest analysis for ImmunityBio.
The appointment of Dr. Jim Yong Kim comes after a strong run in ImmunityBio’s share price, with a year to date share price return of 292.08% and a one year total shareholder return of 225.93%. Recent momentum has been steadier, with a 30 day share price return of 3.12% and a 90 day share price return of 2.06% around the time of the earnings update that reported rising revenue alongside a wider loss, which hints that recent price moves may reflect shifting views on both growth potential and risk.
If you are looking beyond ImmunityBio to other health focused opportunities using artificial intelligence, this could be a useful moment to scan the market through 40 healthcare AI stocks
ImmunityBio is drawing attention for its science and its new global reach, yet the stock has already moved sharply this year. The next step is to determine whether that story is already fully reflected in today’s price.
Most Popular Narrative: 39.1% Undervalued
ImmunityBio’s most followed narrative sets a fair value of $13 per share, well above the recent $7.92 close. This places a lot of weight on future expansion and profitability.
The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.
Want to see how this global rollout links to ambitious revenue growth, rising margins and a richer earnings multiple over time? The narrative spells out the specific assumptions that underpin that $13 fair value and how much needs to go right for ImmunityBio.
Result: Fair Value of $13 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, ImmunityBio’s story could change if new trials fail to broaden ANKTIVA beyond current bladder cancer use, or if regulators take a tougher stance on future approvals.
Find out about the key risks to this ImmunityBio narrative.
Next Steps
With all this in mind, do you feel the current ImmunityBio story leans more towards opportunity or concern? Take a moment to weigh both sides and then review the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond ImmunityBio?
Do not stop with ImmunityBio. Use this moment to broaden your watchlist and identify other stocks that fit your goals before potential opportunities change.
- Explore smaller companies that already show solid fundamentals by scanning the market through 20 elite penny stocks with strong financials.
- Focus on quality stocks that trade at levels different from their estimated worth by working through the 53 high quality undervalued stocks.
- Prioritise resilience and capital preservation by focusing on companies that pass strict balance sheet checks using the solid balance sheet and fundamentals stocks screener (50 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com